Congenital Toxoplasmosis

Relationship to Toxoplasmosis Topic

Transplacental transmission following PRIMARY maternal infection during pregnancy (general organism biology = Toxoplasmosis topic). KEY DISTINCTION: this is primary-infection/transplacental, UNRELATED to CMI status/reactivation — different mechanism from adult reactivation encephalitis covered in Toxoplasmosis.

Timing Pattern — INVERTS the rubella/general TORCH pattern (high-yield exception)

1st trimester: LOWER transmission risk (~10-15%) but MORE SEVERE disease when transmitted. 3rd trimester: HIGHER transmission risk (~60%+) but generally MILDER/asymptomatic at birth. CONTRAST vs rubella: rubella = both risk dimensions align (early = less transmissible AND worse); toxo = dimensions OPPOSITE (early = less transmissible but worse; late = more transmissible but milder). Don’t assume all TORCH share rubella’s pattern.

Clinical

Classic TRIAD (memorize): CHORIORETINITIS + HYDROCEPHALUS + INTRACRANIAL CALCIFICATIONS. Calcifications: DIFFUSE (scattered throughout parenchyma) — CONTRAST vs CMV’s PERIVENTRICULAR pattern (CMV topic) — frequently tested radiological distinction. Broader TORCH constellation also possible (hepatosplenomegaly, jaundice, thrombocytopenia).

Substantial proportion ASYMPTOMATIC at birth → DELAYED CHORIORETINITIS later (months-years, even adolescence) — mirrors CMV’s delayed hearing loss pattern (different organism/mechanism) — asymptomatic infants need LONG-TERM OPHTHALMOLOGICAL FOLLOW-UP.

Screening/Diagnosis

Serial maternal serological screening throughout pregnancy: practiced in some higher-prevalence countries (France = classic universal-screening example). NOT standard/universal in many countries incl. typically not India — reflects cost-effectiveness/prevalence-driven policy variation. Neonatal diagnosis: IgM/IgA serology (true congenital infection, general TORCH IgM principle) + PCR on amniotic fluid (antenatal, post-seroconversion) or neonatal blood/CSF.

Treatment — distinctive therapeutic optimism among TORCH

Spiramycin: maternal infection diagnosed, fetal infection NOT YET confirmed — reduces transplacental transmission risk. Pyrimethamine-sulfadiazine + folinic acid (SAME regimen as adult toxoplasmic encephalitis, Toxoplasmosis topic): once fetal infection CONFIRMED (amniotic PCR) or in confirmed congenital neonate — reduces disease severity. KEY CONTRAST vs congenital rubella (no treatment, prevention-only): here ACTIVE maternal/fetal treatment pathway genuinely exists.

Relationship to Toxoplasmosis’s General Biology

Congenital toxoplasmosis results specifically from transplacental transmission of Toxoplasma gondii following primary (first-time) maternal infection during pregnancy — the organism’s general life cycle, feline definitive host, and dual oocyst/tissue-cyst transmission routes are covered in full under Toxoplasmosis, and this topic focuses specifically on the fetal/congenital consequences, which are genuinely, importantly distinct in mechanism from that topic’s focus on reactivation disease in the immunocompromised host: congenital toxoplasmosis is a primary-infection, transplacental phenomenon, entirely unrelated to CMI status or reactivation, a real, specifically important point of contrast worth holding clearly between these two topics covering the same organism.

A Genuinely Important, Specific Point of Contrast With Rubella’s Timing Pattern

Congenital toxoplasmosis genuinely, specifically inverts the gestational-timing risk pattern established as the general TORCH principle and exemplified cleanly by rubella (see TORCH Complex and Congenital Infections and Congenital Rubella Syndrome) — a real, high-yield, specifically testable point worth remembering precisely as a genuine exception to the general rule: maternal toxoplasmosis infection in the first trimester carries a comparatively lower transmission risk (roughly 10-15%) but, when transmission does occur, produces more severe disease; infection in the third trimester, by contrast, carries a substantially higher transmission risk (potentially 60% or more) but generally produces milder or even asymptomatic disease at birth — this “opposite” pattern relative to rubella (where earlier infection is both less transmissible AND more severe when it occurs, aligning both risk dimensions in the same direction, whereas toxoplasmosis has the two risk dimensions moving in opposite directions across gestation) is a genuinely important, specifically high-yield point of TORCH-group internal contrast worth actively remembering rather than assuming all TORCH infections share rubella’s single risk pattern.

Clinical Manifestations

Congenital toxoplasmosis’s classic triad — genuinely, specifically worth memorizing given its high-yield status — comprises chorioretinitis, hydrocephalus, and intracranial calcifications, with the calcifications characteristically diffuse (scattered throughout the brain parenchyma) rather than the periventricular-predominant pattern described for congenital CMV under Cytomegalovirus Infection — this diffuse-versus-periventricular calcification distinction is, again, a genuinely important, frequently tested point of radiological contrast between these two TORCH infections worth holding in direct comparison. Beyond this triad, the broader TORCH constellation (hepatosplenomegaly, jaundice, thrombocytopenia) can also occur, and, genuinely importantly, a substantial proportion of congenitally infected infants are asymptomatic at birth but go on to develop delayed chorioretinitis (sometimes not manifesting until months to years later, occasionally into adolescence or beyond) — a real, specifically testable point mirroring, in general concept though via a different organism and mechanism, congenital CMV’s own delayed-hearing-loss pattern, and again underscoring why apparently asymptomatic congenitally infected infants require long-term ophthalmological follow-up rather than being considered definitively unaffected.

Screening and Diagnosis

Given toxoplasmosis’s genuine “later infection = more transmissible” pattern, and the real possibility of effective treatment reducing transmission/severity if maternal infection is caught and treated during pregnancy (below), serial maternal serological screening throughout pregnancy is practised in some countries with higher toxoplasmosis prevalence/screening infrastructure (France being the classically cited example of a national universal-screening programme), allowing detection of maternal seroconversion during pregnancy and prompting treatment — though genuinely, universal prenatal toxoplasmosis screening is not standard practice in many countries, including typically not as a routine universal test in India, reflecting genuine variation in national screening policy driven by cost-effectiveness and population-prevalence considerations. Neonatal diagnosis in a suspected case relies on IgM/IgA serology (indicating true congenital infection, per the general TORCH IgM principle) and PCR on amniotic fluid (when performed antenatally, following documented or suspected maternal seroconversion) or neonatal blood/CSF.

Treatment

A genuinely important, distinctive point among TORCH infections: congenital toxoplasmosis has a specific, actionable maternal treatment pathway when maternal infection is identified during pregnancy — spiramycin is used specifically to reduce the risk of transplacental transmission when maternal infection is diagnosed but fetal infection has not yet been confirmed, while pyrimethamine-sulfadiazine (with folinic acid) — the same regimen used for toxoplasmic encephalitis under Toxoplasmosis — is used once fetal infection is confirmed (by amniotic fluid PCR) or in a confirmed congenitally infected neonate, aiming to reduce disease severity. This genuinely represents a real, specifically important point of therapeutic optimism distinguishing congenital toxoplasmosis from congenital rubella (no treatment at all, prevention-only) — here, active, evidence-based maternal/fetal treatment genuinely exists and is used, even though the underlying organism-specific antimicrobial regimen mirrors the one already established for adult reactivation disease under Toxoplasmosis.